anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Number of people suffered from Parkinson disease (PD) is increasing every year. PET imaging of dopamine transport receptors（DAT） serves as the gold standard for the diagnosis and monitoring of PD development. However, due to high costs and radiation reasons, it is not suitable for long-term follow-up. Serum cystatin C can be easily obtained and cheap as an indicator. In recent years, studies have gradually found that it is related to the progression of H\&Y staging of Parkinson's disease. To this extent, we want to further explore whether it can reflect the loss of DAT in the brain. Explore whether it can partially replace the role of DAT imaging for future clinical evaluation.
The invention discloses a bi-zinc-phthalocyanine coordination compound and a preparation method and an application thereof. A molecular structural formula of the bi-zinc-phthalocyanine coordination compound is as described in a specification (I). The preparation method of the bi-zinc-phthalocyanine coordination compound comprises steps of preparing a reaction solution and enabling the reaction solution to be reacted. The above bi-zinc-phthalocyanine coordination compound has no photosensitive activity when being stimulated by red light. A disulfide chemical bond of the bi-zinc-phthalocyanine coordination compound is restored by GSH (Glutathione) in a certain concentration and accordingly a zinc phthalocyanine coordination compound monomer is obtained, the photosensitive capability of the zinc phthalocyanine coordination is restored, a tumor tissue is high in GSH level, and the optical activity of the bi-zinc-phthalocyanine coordination compound is high in targeting of tumor. According to the preparation method of the bi-zinc-phthalocyanine coordination compound, only the reactant beta- single carboxyl replaced zinc phthalocyanine and 2, 2'-disulfanediyldiethanol are reacted, the reaction technology is simple and the target product yield and purity are high. The bi-zinc-phthalocyanine coordination compound can be widely applied to photodynamic drugs or photosensitive drugs.
On each vaccination day the lyophilized antigen/adjuvant/liposome complex is re-suspended in the oil (Montanide 1SA51 VG) before injection. The vaccine is not an emulsion.
PURPOSE: A composition for anticancer containing an inhibitor for flotillin protein or gene is provided to relate to down regulation of signal transduction of Ras protein. CONSTITUTION: A composition for anticancer contains flotillin protein or gene encoding the protein. The flotillin protein has amino acid sequence of sequence number 1. The flotillin gene has sequence of sequence number 2. A flotillin inhibitor is an antibody specifically binding to the flotillin protein. The antibody is monoclonal antibody, polyclonal antibody, mono chain antibody, chimera antibody or peptide mimetics. The composition further contains an apoptosis inducer.
BACKGRUOUND: Reactive oxygen species (ROS) and inflammation are reported to have a fundamental role in the pathogenesis of ischemia-reperfusion (IR) injury, a leading cause of acute kidney injury. The present study investigated the role of pyruvate dehydrogenase kinase 4 (PDK4) in ROS production and inflammation following IR injury.
METHODS: We used a streptozotocin-induced diabetic C57BL6/J mouse model, which was subjected to IR by clamping both renal pedicles. Cellular apoptosis and inflammatory markers were evaluated in NRK-52E cells and mouse primary tubular cells after hypoxia and reoxygenation using a hypoxia work station.
RESULTS: Following IR injury in diabetic mice, the expression of PDK4, rather than the other PDK isoforms, was induced with a marked increase in pyruvate dehydrogenase E1α (PDHE1α) phosphorylation. This was accompanied by a pronounced ROS activation, as well as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-1β (IL-1β), and monocyte chemoattractant protein-1 (MCP-1) production. Notably, sodium dichloroacetate (DCA) attenuated renal IR injury-induced apoptosis which can be attributed to reducing PDK4 expression and PDHE1α phosphorylation levels. DCA or shPdk4 treatment reduced oxidative stress and decreased TNF-α, IL-6, IL-1β, and MCP-1 production after IR or hypoxia-reoxygenation injury.
CONCLUSION: PDK4 inhibition alleviated renal injury with decreased ROS production and inflammation, supporting a critical role for PDK4 in IR mediated damage. This result indicates another potential target for reno-protection during IR injury; accordingly, the role of PDK4 inhibition needs to be comprehensively elucidated in terms of mitochondrial function during renal IR injury.
The skeletal effects of raloxifene treatment were assessed in ovariectomized rats and monkeys. In rats, raloxifene prevented increased bone resorption and bone loss after ovariectomy. There were positive effects of raloxifene on bone strength, but the effects varied with time. Cynomolgus monkeys were treated with raloxifene or conjugated estrogens for 2 years. In terms of bone cycles, this is equivalent to approximately 6 years in humans. Raloxifene and estrogen suppressed bone turnover and increased BMD in the lumbar spine and in the central cancellous bone of the proximal tibia. In this animal model, there was a positive correlation between vertebral compressive breaking force and BMD of the lumbar spine. 

Histologic examination of bone from rats and monkeys treated with raloxifene showed no evidence of woven bone, marrow fibrosis, or mineralization defects.

These results are consistent with data from human studies of radiocalcium kinetics and markers of bone metabolism, and are consistent with the action of raloxifene hydrochloride as a skeletal antiresorptive agent.
BACKGROUND: The combination of Astragalus membranaceus and Carthamus tinctorius (AC) exhibits significant therapeutic effects in cerebral ischemia/reperfusion injury (CIRI). Understanding the metabolic characteristics of brain microregions and disturbances in tissues and systemic circulation is crucial for elucidating the mechanisms of CIRI and the therapeutic benefits of AC. However, in situ metabolic regulation of the complex brain structure has not been adequately studied, and the therapeutic mechanism of AC requires immediate clarification.
PURPOSE: The present study aimed to unveil the specific metabolic reprogramming of CIRI at systemic and microregional levels, identify key metabolic pathways and metabolites, and elucidate the therapeutic mechanisms of AC.
METHODS: Air flow-assisted desorption electrospray ionization mass spectrometry imaging (AFADESI-MSI), a newly developed technique, was used to investigate metabolites in brain microregions. Hematoxylin-eosin, Nissl, and immunofluorescence staining were performed to visualize the microscopic changes associated with spatial metabolism. A comprehensive metabolomics study was conducted on serum, brain tissue, and microregions, along with neurological assessments, cerebral infarction measurements, and Evans blue experiments, to assess the systemic and local metabolic effects of AC treatment for CIRI.
RESULTS: AC significantly reduced neurological damage, minimized infarct size, and repaired blood-brain barrier damage in CIRI rats. AFADESI-MSI demonstrated that the metabolic imbalance caused by CIRI primarily occurs in the cerebral cortex, hippocampus, caudate putamen, thalamus, cerebellar cortex, and fiber tract regions. Significant changes in 16 metabolites were observed in these regions, corresponding to neuron damage, glial cell activation, and neural repair. 20 metabolites from serum and 4 from brain tissue varied significantly with the sham group. Comprehensive metabolomics analysis indicated a close relationship among serum, tissue, and microregional metabolism. CIRI-induced systemic and localized metabolic disorders involve 14 metabolic pathways. AC conferred therapeutic benefits in CIRI by reversing various metabolic imbalances.
CONCLUSION: AFADESI-MSI efficiently visualized brain microregion metabolism. Comprehensive metabolomics analysis revealed detailed insights into the specific metabolic reprogramming in CIRI and the therapeutic impacts of AC. AC demonstrated significant clinical potential as an adjunct therapy to existing CIRI treatments.
There is only one arm. Three hand modules; Dye-VL 500-600nm, High Power QSW 1064nm, and High power Pixel ER:YAG 2940nm laser module with rollers will be utilized in combination in a series of treatments intended to improve skin color, tone, texture and laxity. Subjects will receive up to four treatments administered in intervals of 28 +/- 2 days. Treatment duration of approximately 60 minutes.
The present invention relates to aerosol hair care products having reduced Volatile Organic Compound (VOC) content. Environmental sustainability has become an increasing concern in aerosol applications. Products that release less propellant (e.g., volatile Organic Compounds (VOCs)) than traditional aerosols are environmentally friendly. There remains a need for aerosol products having compressed gas as a propellant while maintaining product performance, lifetime, and/or minimizing residual product. It is therefore an object of the present invention to provide an aerosol product having a compressed gas (e.g., nitrogen) as a propellant while maintaining product performance, lifetime, and/or minimizing residual product. It has been found that the product properties of aerosol products using compressed gas as propellant can be maintained by a specific valve configuration controlling the spray rate in combination with the pressure in the container. Valve bagThe valve comprises a valve body, wherein the valve body comprises a valve rod and a spring device; the valve comprises a restricted tail (RTP, 14) with a diameter of 0.50mm to 0.55mm and a gas phase tap (VPT, 15) with a diameter of 0.30mm to 0.34 mm. The pressure in the vessel being from (9) to (11) bar (9 x10  5  To (11) x10  5  Pa. The hair care formulation comprises (3) to 15% starch by total weight of the formulation and propellant.
PROBLEM TO BE SOLVED: To obtain a compound useful for producing a composition excellent in waving effects and persistence, low damaging properties to damaged hair, blending and low odor properties and safety when used as a reducing agent for a permanent waving composition. SOLUTION: This polyalkylene glycol monothiolactate of formula I [R<1> is ethylene or propylene; (n) is an integer of 2-4], e.g. diethylene glycol monothiolactate. The compound of formula I is obtained by reacting 1mol equiv. thiolactic acid or alkyl thiolactate of formula II (R<2> is H or a 1-4C alkyl) with preferably 1.5-3mol equiv. polyalkylene glycol of formula III at 80-180 deg.C. Water produced at this time is preferably removed. Furthermore, the compound of formula I as a reducing agent in a blended amount of 5-30% is mixed in an aqueous medium and the pH is preferably regulated to 6.5-8 to afford an excellent permanent waving composition.
In clinical practice of moxibustion, Professor CHEN Rixin has found that many symptoms are related to yang deficiency, cold and dampness accumulation or yang deficiency, and the obstruction of qi and blood. The therapeutic effects on these symptoms are not satisfactory with either herbal medication or western drugs. But, the effects can be obviously improved by replenishing yang with heat-sensitive moxibustion and medication in combination. Hence, he has proposed the academic view, "synergistic effect of moxibustion combined with medication", based on which, the enhanced yang qi may accelerate the actions of medication. Guided by this academic view, the tumor rehabilitation is conducted. In clinic, the heat-sensitive moxibustion is combined with immune targeting therapy or chemotherapy, which obviously inhibits tumor, reduces the adverse reactions of drugs, improves the quality of life and extends the life span of tumor patients. It is anticipated to launch a new pattern of moxibustion-medication collaboration to improve the clinical therapeutic effect on tumor through the synergistic effect of the coordination of yang qi and medication.
Stereotactic radiotherapy will be delivered in 1-5 fractions to each brain metastases according to the volume and location of the metastases and clinician discretion. Osimertinib will start 1-7 days post radiotherapy.
The program will be carried out 3 days a week, with pulmonary rehabilitation in each session, for a total of 45-60 minutes, for 8 weeks. The training of children whose evaluations are completed will begin after individually structured pulmonary rehabilitation and trunk control training programs are created. The content of pulmonary rehabilitation will consist of diaphragmatic breathing, pursed-lip breathing, segmental breathing, and IMT. Exercises and activities for trunk muscle activation, pelvic control, and proximal stabilization will be used together with trunk and gluteal muscle strengthening exercises. The intensity and level of exercises will be increased gradually. Body control work will first start on hard ground and then continue on soft ground and dynamic surfaces. All trunk control training will be applied actively or actively assisted.
The objective of this study was to compare effects of liraglutide and placebo over 16 weeks on gastric motor functions, satiation, satiety and weight in obese patients. Subjects were randomized to liraglutide or placebo. Liraglutide or placebo was escalated by 0.6mg/day each week for 5 weeks and continued until week 16. At baseline and after 16 weeks' treatment, the investigators measured weight, gastric emptying of solids (GES), gastric volumes, satiation (maximum tolerated volume of liquid nutrient drink), and satiety. GES was also measured at 5 weeks.

During the study, the subjects received standardized dietetic and behavioral advice for weight reduction therapy. All subjects were given a standard text for information and met with a behavioral psychologist who has expertise in obesity treatment at the baseline visit and at visits at weeks 4,8, and 12. Additionally, the subjects had brief contact with a member of the study team every 4 weeks to inquire about their adherence to study protocol, any difficulties they were experiencing, whether they were reading their text assignments, and to answer any additional questions.
Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy (DAV) has shown safety and efficacy in eligible patients with newly diagnosed acute myeloid leukemia (AML). However, there are no direct comparisons between DAV and 3 + 7 daunorubicin and cytarabine chemotherapy (DA) alone. We performed a propensity score-matched analysis to compare the outcomes of DAV group with historical DA group and identify the clinical and molecular characteristics of patients who might benefit from the DAV regimen. The DAV group had a higher Complete remission (CR) rate than the DA group (90% vs. 55%, p = 0.008). 25 (96%) patients in the DAV group had a higher MRD-negative CRc rate compared with 13 (62%) patients in the DA group (p = 0.006). After a median follow-up duration of 19.15 (IQR 17.13-21.67) months, the DAV group had an improved overall survival (p = 0.001) and event-free survival (p = 0.069), but not disease-free survival (p = 0.136). Collectively, DAV regimen induced high CR rates and deep MRD-negative CRc rates after one cycle of induction therapy, as well as prolonged the overall survival, in young adult patients with AML who were eligible for intensive chemotherapy. The addition of venetoclax to intensive chemotherapy should be considered in the future to achieve better survival advantages in eligible AML patients.
UITTREKSEL The present disclosure discloses a cosmetic preparation using Hedychium coronarium as an anti—aging skin care factor and the preparation method thereof. The cosmetic preparation is composed of 6.01—30.5% by weight of a base material, 5—75% by weight of an 5 oil—phase raw material and 15—85% by weight of a water—phase raw material, wherein, the base material is composed of 5—20% by weight of a Hedychium coronarium gel lyophilized powder, l—lO% by weight of vitamin E and 0.01—0.5% by weight of hyaluronic acid. The present disclosure has the cosmetic effects of anti—free lO radicals, anti—oxidation, anti—radiation, anti—bacteria, promoting skin cell proliferation, preventing skin oxidative damage, reducing melanin synthesis, and delaying the skin aging, etc., has no irritation or allergic reactions to skin and mucous membranes, and can endow the product with unique fragrance of Hedychium l5 coronarium. Thus, it can be used in creams, emulsions, cleansing lotions, facial masks and other skin care agents. (+ Fig. l)
The FFMI was calculated as follows: FFMI = fat-free mass (kg)/height squared (m2). FFMI cut-off values (derived from BIA measurements, \</≥15 kg/m2 for females and \</≥17 kg/m2 for males). Patients with esophagogastric cancer were then divided into the normal FFMI group (FFMI ≥17 kg/m2 for male and FFMI ≥15 kg/m2 for female).
The utility model relates to an internal distraction pill used in the gynecology. At present, the prevalence rate of the married women who get the gynecologic diseases is mentioned to be 87.5% according to <<The Report for the Heath Situation of Women>>. The caused symptoms such as the dim complexion, colored spot, lassitude of waist and kneel, irregular menstruation, dysmenorrhea, leukorrhagia will occupy 95%. The existing cleaning liquid can only clean the   vulva while the effervescent tablets can be put into the vagina but can not be taken out which causes the residue to stay in the vagina. The external surface of the utility model is provided with a mesh membrane provided with a draft line by which the pill can be taken out after being used. The utility model which does not influence the daily work has the advantages of convenient use and safety.
Preoperative records will be taken (photos, conventional periapical radiographs, and impression to construct acrylic stent to help standardization on follow up apical radiographs). Administration of inferior alveolar nerve block then using rubber dam isolation one of the investigators will remove the caries using large round but under copious amount of coolant and if carious exposure occur, part of the pulp chamber will be removed using sharp spoon excavator. Then the pulp status will be assessed if bleeding is controlled with direct irrigation with distilled water for 2 minutes then next step will be taken but if not continue excavation of the pulp till bleeding is controlled. if bleeding is not controlled after performing complete pulpotomy, tooth will be excluded from the study Then direct application of capping materials (TheraCal or MTA) according to manufacturer instructions, then Riva self-cure glass-ionomer base and composite resin final restoration. One of the investigators will take immediate standardized postoperative periapical radiographs. Follow-up will be for 12 months. Pre-calibrated blinded dentists will assess out comes separately.
SUPRAX is available for oral administration in the following dosage forms and strengths:

  * Film-coated tablets provide 400 mg of cefixime as trihydrate. These are white to off-white, film-coated, capsule shaped tablets with beveled edges and a divided score line on each side. The tablet is debossed with "SUPRAX" across one side and "LUPIN" across the other side.
  * Capsules provide 400 mg of cefixime as trihydrate. These are size "00EL" capsules with pink opaque cap and pink opaque body with "LU" on the cap and "U43" on the body in black ink. Capsules contain white to yellowish white granular powder.
  * Chewable tablets provide either 100 mg or 150 mg or 200 mg of cefixime as trihydrate. The 100 mg tablet is pink, round tablet, debossed with "SUPRAX 100" on one side and "LUPIN" on other side. The 150 mg tablet is pink, round tablet, debossed with "SUPRAX 150" on one side and "LUPIN" on other side. The 200 mg tablet is pink, round tablet, debossed with "SUPRAX 200" on one side and "LUPIN" on other side.
  * Powder for oral suspension, when reconstituted, provides either 100 mg/5 mL or 200 mg/5 mL or 500 mg/5 mL of cefixime as trihydrate. For 100 mg/5 mL and 200 mg/5 mL, the powder has an off white to pale yellow color and is strawberry flavored. For 500 mg/5 mL, the powder has an off white to cream color and is strawberry flavored.
Asylum seekers and refugees will be randomized to receive the SH+ intervention or Enhanced Treatment as Usual. The SH+ has been developed by WHO and collaborators working in the humanitarian field, with expertise in global mental health and psychosocial interventions. SH+ consists of a pre-recorded audio course, delivered by facilitators in a group setting and complemented with an illustrated self-help book. SH+ was designed to be relevant for large adversity-affected populations: it is transdiagnostic, easily adaptable to different cultures and languages, and both meaningful and safe for people with and without mental disorders. The format of SH+ is innovative in that it seeks to ensure that key intervention components are delivered as intended without the burden of extensive facilitator training. SH+ programme is based on acceptance and commitment therapy (ACT), a form of cognitive-behavioral therapy, with distinct features. SH+ programme has two components: a pre-recorded course and an illustrated self-help book. Pre-recorded audio material (culturally adapted) is delivered across five 2-hour sessions to groups of up to 30 people. The audio material imparts key information about stress management and guides participants through individual exercises and small group discussions. To augment the audio recordings, an illustrated self-help book reviews all essential content and concepts 19. Written manuals help briefly-trained, non-specialist facilitators to conduct the course using the pre-recorded audio. The SH+ intervention will be delivered by briefly-trained, non-specialist facilitators.

The control intervention will receive Enhanced Treatment as Usual.
The study will be conducted by nurses at 3 postoperative units with children and adolescents after surgery. All nurses working with patients in these units will be asked to participate. Tailored Educational Intervention is administered to this group.
Hydrochlorothiazide (hydrochlorothiazide, USP 12.5 mg) is the 3,4-dihydro derivative of chlorothiazide. Its chemical name is 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Its empirical formula is C7H8ClN3O4S2; its molecular weight is 297.74; and its structural formula is:

It is a white, or practically white, crystalline powder which is slightly soluble in water, but freely soluble in sodium hydroxide solution.

Hydrochlorothiazide capsules, USP are supplied as 12.5 mg capsules for oral use.

Inactive ingredients: colloidal silicon dioxide, corn starch, lactose monohydrate, magnesium stearate. The hard gelatin shell consists of gelatin, titanium dioxide, sodium lauryl sulfate, FD&C Blue #1, FD&C Red #3. The capsules are printed with black ink containing shellac, dehydrated alcohol, isopropyl alcohol, butyl alcohol, propylene glycol, strong ammonia solution, black iron oxide, and potassium hydroxide.